Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 10,757 shares of the business’s stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the sale, the chief financial officer now owns 215,340 shares in the company, valued at $2,597,000.40. This represents a 4.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Mineralys Therapeutics Price Performance

Shares of MLYS stock opened at $13.88 on Wednesday. The company has a market cap of $871.46 million, a PE ratio of -3.81 and a beta of -0.39. Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $18.38. The stock’s 50 day simple moving average is $12.36 and its two-hundred day simple moving average is $12.34.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. Equities research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Institutional Investors Weigh In On Mineralys Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MLYS. BNP Paribas Financial Markets bought a new position in Mineralys Therapeutics during the 4th quarter valued at about $48,000. ProShare Advisors LLC purchased a new position in shares of Mineralys Therapeutics during the fourth quarter valued at approximately $128,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Mineralys Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after buying an additional 989 shares during the period. GAMMA Investing LLC grew its stake in shares of Mineralys Therapeutics by 9,602.2% during the first quarter. GAMMA Investing LLC now owns 8,829 shares of the company’s stock valued at $140,000 after buying an additional 8,738 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Mineralys Therapeutics in the fourth quarter worth approximately $145,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on MLYS shares. The Goldman Sachs Group reduced their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th. Finally, HC Wainwright increased their price objective on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, April 2nd.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.